Lisamarie Fahy

Lisamarie Fahy joined Omega with over 30 years of clinical experience, including expertise in clinical trial management and delivery of high-quality clinical development programs through global registration and approval, regulatory submissions with the FDA, EMEA and PMDA, marketing approvals and GCP compliance and inspections. Her experience spans both academic and industry settings with expertise in gene therapy, cardiovascular space, oncology and rare disease programs.

Most recently, Ms. Fahy was Vice President, Head of Clinical Development Operations at AVROBIO. Prior to AVROBIO, she served as Head of Global Clinical Development Operations at both H3 Biomedicine and Aegerion Pharmaceuticals. She also held various clinical development roles of increasing responsibility at Shire Pharmaceuticals and Wyeth Research. Ms. Fahy began her career as a clinical research and program coordinator at the Brigham and Women’s Hospital.

Ms. Fahy received an B.S. in Physiology from the University of Massachusetts.